1.000000
0.000000
0.000000
0.000000
1.000000
0.000000
0.000000
0.000000
1.000000
0.00000
0.00000
0.00000
Li, H.
Bowling, J.J.
Hamann, M.T.
Jung, J.H.
http://mmcif.pdb.org/dictionaries/ascii/mmcif_pdbx.dic
C3 H7 N O2
89.093
y
ALANINE
L-peptide linking
C4 H8 N2 O3
132.118
y
ASPARAGINE
L-peptide linking
C4 H7 N O4
133.103
y
ASPARTIC ACID
L-peptide linking
C3 H7 N O2 S
121.158
y
CYSTEINE
L-peptide linking
C5 H9 N O4
147.129
y
GLUTAMIC ACID
L-peptide linking
C2 H5 N O2
75.067
y
GLYCINE
peptide linking
C6 H13 N O2
131.173
y
ISOLEUCINE
L-peptide linking
C6 H13 N O2
131.173
y
LEUCINE
L-peptide linking
C5 H7 N O3
129.114
n
PYROGLUTAMIC ACID
L-peptide linking
C9 H11 N O2
165.189
y
PHENYLALANINE
L-peptide linking
C5 H9 N O2
115.130
y
PROLINE
L-peptide linking
C3 H7 N O3
105.093
y
SERINE
L-peptide linking
C4 H9 N O3
119.119
y
THREONINE
L-peptide linking
C9 H11 N O3
181.189
y
TYROSINE
L-peptide linking
C5 H11 N O2
117.146
y
VALINE
L-peptide linking
To be Published
0353
Sponge Derived Linear Knottins as a Novel Scaffold for Oral Peptide Drug Administration
10.2210/pdb2lzx/pdb
pdb_00002lzx
3905.369
Asteropsin B
1
nat
polymer
no
yes
(PCA)GCAFEGESCNVEFYPCCPGLGLTCIPGNPDGTCYYL
QGCAFEGESCNVEFYPCCPGLGLTCIPGNPDGTCYYL
A
polypeptide(L)
n
n
n
n
n
n
n
n
n
n
n
n
n
n
n
n
n
n
n
n
n
n
n
n
n
n
n
n
n
n
n
n
n
n
n
n
n
sample
350938
Asteropus
entity_poly
pdbx_struct_mod_residue
struct_conn
database_2
pdbx_database_status
repository
Initial release
Derived calculations
Polymer sequence
Database references
Other
1
0
2013-10-23
2
0
2019-12-25
2
1
2023-06-14
_entity_poly.pdbx_seq_one_letter_code_can
_pdbx_struct_mod_residue.parent_comp_id
_struct_conn.pdbx_leaving_atom_flag
_database_2.pdbx_DOI
_database_2.pdbx_database_accession
_pdbx_database_status.status_code_nmr_data
BMRB
Y
RCSB
2012-10-11
REL
REL
REL
REL
structures with the lowest energy
200
20
2D DQF-COSY
2D 1H-1H TOCSY
2D 1H-1H NOESY
2D 1H-13C HSQC
10
mM
7.0
ambient
298
K
simulated annealing
1
lowest energy
10 mM ABU8-2, DMSO-d6
DMSO-d6
Brunger, Adams, Clore, Gros, Nilges and Read
structure solution
CNS
1.3
Brunger, Adams, Clore, Gros, Nilges and Read
refinement
CNS
1.3
600
Varian
INOVA
Varian INOVA
500
Varian
INOVA
Varian INOVA
PCA
1
n
1
PCA
1
A
GLY
2
n
2
GLY
2
A
CYS
3
n
3
CYS
3
A
ALA
4
n
4
ALA
4
A
PHE
5
n
5
PHE
5
A
GLU
6
n
6
GLU
6
A
GLY
7
n
7
GLY
7
A
GLU
8
n
8
GLU
8
A
SER
9
n
9
SER
9
A
CYS
10
n
10
CYS
10
A
ASN
11
n
11
ASN
11
A
VAL
12
n
12
VAL
12
A
GLU
13
n
13
GLU
13
A
PHE
14
n
14
PHE
14
A
TYR
15
n
15
TYR
15
A
PRO
16
n
16
PRO
16
A
CYS
17
n
17
CYS
17
A
CYS
18
n
18
CYS
18
A
PRO
19
n
19
PRO
19
A
GLY
20
n
20
GLY
20
A
LEU
21
n
21
LEU
21
A
GLY
22
n
22
GLY
22
A
LEU
23
n
23
LEU
23
A
THR
24
n
24
THR
24
A
CYS
25
n
25
CYS
25
A
ILE
26
n
26
ILE
26
A
PRO
27
n
27
PRO
27
A
GLY
28
n
28
GLY
28
A
ASN
29
n
29
ASN
29
A
PRO
30
n
30
PRO
30
A
ASP
31
n
31
ASP
31
A
GLY
32
n
32
GLY
32
A
THR
33
n
33
THR
33
A
CYS
34
n
34
CYS
34
A
TYR
35
n
35
TYR
35
A
TYR
36
n
36
TYR
36
A
LEU
37
n
37
LEU
37
A
author_defined_assembly
1
monomeric
A
PCA
1
PYROGLUTAMIC ACID
A
PCA
1
GLN
1.0000000000
0.0000000000
0.0000000000
0.0000000000
1.0000000000
0.0000000000
0.0000000000
0.0000000000
1.0000000000
1_555
x,y,z
identity operation
0.0000000000
0.0000000000
0.0000000000
A
N
CYS
10
A
N
CYS
10
A
O
GLY
32
A
O
GLY
32
A
O
TYR
35
A
O
TYR
35
A
N
THR
24
A
N
THR
24
1
A
PHE
14
-148.72
-45.02
1
A
TYR
15
-115.56
74.20
2
A
PHE
14
-148.91
-44.97
2
A
TYR
15
-115.61
74.16
3
A
PHE
14
-148.80
-45.01
3
A
TYR
15
-115.58
74.21
4
A
PHE
14
-149.03
-45.20
4
A
TYR
15
-115.49
74.16
5
A
PHE
14
-148.90
-45.07
5
A
TYR
15
-115.57
74.20
6
A
PHE
14
-148.84
-45.13
6
A
TYR
15
-115.55
74.18
7
A
PHE
14
-149.09
-45.01
7
A
TYR
15
-115.67
74.13
8
A
PHE
14
-148.91
-44.96
8
A
TYR
15
-115.45
73.99
9
A
PHE
14
-148.95
-45.12
9
A
TYR
15
-115.64
74.17
10
A
PHE
14
-148.82
-45.02
10
A
TYR
15
-115.57
74.27
10
A
CYS
17
-69.96
-177.73
11
A
PHE
14
-148.98
-45.01
11
A
TYR
15
-115.59
74.20
12
A
PHE
14
-149.03
-44.75
12
A
TYR
15
-115.47
73.92
13
A
PHE
14
-148.81
-45.01
13
A
TYR
15
-115.42
74.05
14
A
PHE
14
-148.94
-45.00
14
A
TYR
15
-115.63
74.22
15
A
PHE
14
-149.02
-45.05
15
A
TYR
15
-115.58
74.10
16
A
PHE
14
-148.80
-44.97
16
A
TYR
15
-115.44
74.07
17
A
PHE
14
-147.54
-44.94
17
A
TYR
15
-115.69
74.20
18
A
PHE
14
-149.06
-45.13
18
A
TYR
15
-115.58
74.15
19
A
PHE
14
-148.97
-44.86
19
A
TYR
15
-115.38
74.07
20
A
PHE
14
-148.78
-45.02
20
A
TYR
15
-115.69
74.22
Solution NMR structure of Asteropsin B from a marine sponge Asteropus sp.
1
N
N
disulf
2.032
A
CYS
3
A
SG
CYS
3
1_555
A
CYS
18
A
SG
CYS
18
1_555
disulf
2.028
A
CYS
10
A
SG
CYS
10
1_555
A
CYS
25
A
SG
CYS
25
1_555
disulf
2.031
A
CYS
17
A
SG
CYS
17
1_555
A
CYS
34
A
SG
CYS
34
1_555
covale
1.336
both
A
PCA
1
A
C
PCA
1
1_555
A
GLY
2
A
N
GLY
2
1_555
TOXIN
KNOTTIN, SPONGE, TOXIN
A
ILE
26
A
ILE
26
1
A
PRO
27
A
PRO
27
-0.10
A
ASN
29
A
ASN
29
1
A
PRO
30
A
PRO
30
-0.18
A
ILE
26
A
ILE
26
2
A
PRO
27
A
PRO
27
-0.02
A
ASN
29
A
ASN
29
2
A
PRO
30
A
PRO
30
-0.24
A
ILE
26
A
ILE
26
3
A
PRO
27
A
PRO
27
-0.12
A
ASN
29
A
ASN
29
3
A
PRO
30
A
PRO
30
-0.18
A
ILE
26
A
ILE
26
4
A
PRO
27
A
PRO
27
-0.12
A
ASN
29
A
ASN
29
4
A
PRO
30
A
PRO
30
-0.27
A
ILE
26
A
ILE
26
5
A
PRO
27
A
PRO
27
-0.12
A
ASN
29
A
ASN
29
5
A
PRO
30
A
PRO
30
-0.21
A
ILE
26
A
ILE
26
6
A
PRO
27
A
PRO
27
-0.08
A
ASN
29
A
ASN
29
6
A
PRO
30
A
PRO
30
-0.20
A
ILE
26
A
ILE
26
7
A
PRO
27
A
PRO
27
-0.12
A
ASN
29
A
ASN
29
7
A
PRO
30
A
PRO
30
-0.13
A
ILE
26
A
ILE
26
8
A
PRO
27
A
PRO
27
-0.15
A
ASN
29
A
ASN
29
8
A
PRO
30
A
PRO
30
-0.16
A
ILE
26
A
ILE
26
9
A
PRO
27
A
PRO
27
-0.24
A
ASN
29
A
ASN
29
9
A
PRO
30
A
PRO
30
-0.17
A
ILE
26
A
ILE
26
10
A
PRO
27
A
PRO
27
-0.01
A
ASN
29
A
ASN
29
10
A
PRO
30
A
PRO
30
-0.17
A
ILE
26
A
ILE
26
11
A
PRO
27
A
PRO
27
-0.11
A
ASN
29
A
ASN
29
11
A
PRO
30
A
PRO
30
-0.11
A
ILE
26
A
ILE
26
12
A
PRO
27
A
PRO
27
-0.08
A
ASN
29
A
ASN
29
12
A
PRO
30
A
PRO
30
-0.21
A
ILE
26
A
ILE
26
13
A
PRO
27
A
PRO
27
-0.04
A
ASN
29
A
ASN
29
13
A
PRO
30
A
PRO
30
-0.16
A
ILE
26
A
ILE
26
14
A
PRO
27
A
PRO
27
-0.10
A
ASN
29
A
ASN
29
14
A
PRO
30
A
PRO
30
-0.13
A
ILE
26
A
ILE
26
15
A
PRO
27
A
PRO
27
-0.22
A
ASN
29
A
ASN
29
15
A
PRO
30
A
PRO
30
-0.20
A
ILE
26
A
ILE
26
16
A
PRO
27
A
PRO
27
-0.11
A
ASN
29
A
ASN
29
16
A
PRO
30
A
PRO
30
-0.11
A
ILE
26
A
ILE
26
17
A
PRO
27
A
PRO
27
-0.19
A
ASN
29
A
ASN
29
17
A
PRO
30
A
PRO
30
-0.02
A
ILE
26
A
ILE
26
18
A
PRO
27
A
PRO
27
-0.17
A
ASN
29
A
ASN
29
18
A
PRO
30
A
PRO
30
-0.12
A
ILE
26
A
ILE
26
19
A
PRO
27
A
PRO
27
-0.20
A
ASN
29
A
ASN
29
19
A
PRO
30
A
PRO
30
-0.18
A
ILE
26
A
ILE
26
20
A
PRO
27
A
PRO
27
-0.01
A
ASN
29
A
ASN
29
20
A
PRO
30
A
PRO
30
-0.15
2LZX
PDB
1
2LZX
1
37
2LZX
1
37
2LZX
A
1
1
37
3
anti-parallel
anti-parallel
A
SER
9
A
SER
9
A
ASN
11
A
ASN
11
A
ASP
31
A
ASP
31
A
TYR
36
A
TYR
36
A
LEU
23
A
LEU
23
A
ILE
26
A
ILE
26